January 2027 biotech catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

44 verified catalyst event(s) dated in January 2027, each linked to its official source. Verified as of 2026-09-20.

Date	Event	Company	Drug	Official source & verification
2027-01 (month) in 3mo ESTIMATED	READOUT A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Pa Phase 2 · Glioblastoma	Imvax	IGV-001 Cell Immunotherapy, SOC: Temozol	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients Phase 3 · Lymphoma, Mantle-Cell	Loxo Oncology, Inc.	Pirtobrutinib, Ibrutinib, Acalabrutinib,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-01 in 3mo ESTIMATED	READOUT Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally Phase 2 · Smallpox	SIGA SIGA TECHNOLOGIES INC	Tecovirimat, Smallpox and Mpox Vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Phase 1/2 · Prevention of Rejection in Kidney Transplant	ELDN Eledon Pharmaceuticals, Inc.	AT-1501	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixib Phase 2 · Primary Biliary Cholangitis, PBC	MIRM Mirum Pharmaceuticals, Inc.	Volixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treat Phase 2 · Port-wine Birthmarks, Port-Wine Stain	Shanghai Fudan-Zhangjiang Bio-Phar	Hemopfin+Green Light, Vehicle+Green Ligh	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Safety and Efficacy Study of Treatment Combinations With and Without Chemother Phase 2 · Gastrointestinal Tract Malignancies	RCUS Arcus Biosciences, Inc.	Domvanalimab, Quemliclustat, Zimberelima	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Assess Safety and Efficacy of VAD044 in HHT Patients Phase 1/2 · Hereditary Hemorrhagic Telangiectasia (HHT)	Vaderis Therapeutics AG	VAD044 Part I, VAD044 Part II	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) Phase 2 · Duchenne Muscular Dystrophy	EWTX Edgewise Therapeutics, Inc.	Sevasemten Dose 1, Sevasemten Dose 2, Se	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate i Phase 2 · Soft Tissue Sarcoma	QBiotics Group Limited	Tigilanol Tiglate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti Phase 1/2 · Advanced Solid Tumors	LigaChem Biosciences, Inc.	LCB84, Anti-PD-1 monoclonal antibody	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Phase 1/2 · Neovascular Age-related Macular Degeneration	Skyline Therapeutics (US) Inc.	SKG0106	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Act Phase 2 · Ulcerative Colitis	GILD GILEAD SCIENCES, INC.	Tilpisertib Fosmecarbil	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Phase 2 · Leukemia, Myeloid, Acute	OncoVerity, Inc.	Cusatuzumab, Venetoclax, Azacitidine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation Phase 1/2 · Solid Tumors	Jacobio Pharmaceuticals Co., Ltd.	JAB-30355, JAB-30355	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia Phase 2 · Friedreich Ataxia	LRMR Larimar Therapeutics, Inc.	CTI-1601	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obst Phase 3 · Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy	LXRX LEXICON PHARMACEUTICALS, INC	Sotagliflozin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Phase 3 · Osteogenesis Imperfecta	RARE Ultragenyx Pharmaceutical In	setrusumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem- Phase 2 · Acute Pyelonephritis, Complicated Urinary Tract Infection	Rempex (a wholly owned subsidiary	Meropenem-Vaborbactam, Antibiotics	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids Phase 3 · Atopic Dermatitis	ABBV AbbVie Inc.	Upadacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With A Phase 1/2 · Chronic Kidney Disease Stage 3	AION Healthspan, Inc.	AION-301	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumors	CStone Pharmaceuticals	CS2009, CS2009, Pemetrexed, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" Phase 2 · Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis	Hope Biosciences Research Foundati	Autologous HB-adMSCs	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeti Phase 1/2 · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer	Marengo Therapeutics, Inc.	STAR0602, Sacituzumab Govitecan (SG)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT An Interventional Study of Infigratinib in Children With Hypochondroplasia Phase 2/3 · Hypochondroplasia	QED Therapeutics, a BridgeBio comp	infigratinib 0.128 mg/kg/day, infigratin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT An Open-Label Study of Azetukalner in Major Depressive Disorder Phase 3 · Major Depressive Disorder	XENE Xenon Pharmaceuticals Inc.	Azetukalner	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Agg Phase 2 · Epidermolysis Bullosa Simplex	BioMendics, LLC	5% TolaSure Topical Gel, Topical Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT PSMA PET Combined With MRI for the Detection of PCa Phase 3 · PCA, Prostate Cancer	Telix Pharmaceuticals (Innovations	68Ga-PSMA-11	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face a Phase 3 · Actinic Keratosis	Sun Pharmaceutical Industries, Inc	Reformulated Levulan Kerastick containin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Phase 3 · Actinic Keratosis	Sun Pharmaceutical Industries, Inc	Reformulated Levulan Kerastick containin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Study of COYA 302 for the Treatment of ALS Phase 2/3 · Amyotrophic Lateral Sclerosis (ALS)	COYA Coya Therapeutics, Inc.	COYA 302	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Melli Phase 2 · Obese, Obesity	Hanmi Pharmaceutical Company Limit	HM15275	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immu Phase 3 · Pneumococcal Vaccines	PCVX Vaxcyte, Inc.	31 valent pneumococcal conjugate vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study of NTX-1472 in Social Anxiety Disorder Phase 2 · Social Anxiety Disorder (SAD)	Newleos Therapeutics, Inc.	NTX-1472	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Phase 3 · Focal Epilepsy	PRAX Praxis Precision Medicines,	40 mg/day vormatrogine for 12 weeks, 30	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU Phase 2 · Diabetic Foot Ulcers (DFUs)	LABT Lakewood-Amedex Biotherapeut	Antimicrobial agent	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01 (month) in 3mo ESTIMATED	READOUT A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Phase 2 · KCNT1-Related Epilepsy	Actio Biosciences, Inc.	ABS-1230	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-04 in 4mo ESTIMATED	READOUT A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gas Phase 3 · Gastroesophageal Cancer	Merck Sharp & Dohme LLC	Sacituzumab tirumotecan, Trifluridine-Ti	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-04 in 4mo ESTIMATED	READOUT A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH Phase 3 · Heterozygous Familial Hypercholesterolaemia	AZN ASTRAZENECA PLC	AZD0780	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-06 in 4mo ESTIMATED	READOUT Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Phase 3 · Systemic Sclerosis, Scleroderma	AZN ASTRAZENECA PLC	Anifrolumab (blinded), Anifrolumab (unbl	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-06 in 4mo ESTIMATED	READOUT A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Dis Phase 1/2 · Thyroid Eye Disease	AMGN AMGEN INC	AMG 732	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-06 in 4mo ESTIMATED	READOUT A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickl Phase 1/2 · Anemia, Sickle Cell, Healthy Volunteers	BMY BRISTOL MYERS SQUIBB CO	BMS-986470, Famotidine, Pantoprazole	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-06 in 4mo ESTIMATED	READOUT A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent Phase 1/2 · Chronic Graft-versus-host-disease	INCY INCYTE CORP	INCA034176	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-07 in 4mo ESTIMATED	READOUT Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children Phase 3 · Sickle Cell Disease	SNY Sanofi	PCV21, 20vPCV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change